Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0779 • ACR Convergence 2023
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Laura PINA VEGAS¹, Laetitia Penso², Emilie Sbidian³ and pascal claudepierre⁴, ¹Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France, ²Université Paris Est Créteil, Créteil, France, ³Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁴Universitary Henri Mondor Hospital, Creteil, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…
Abstract Number: 1396 • ACR Convergence 2023
Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses
Luis Coronel¹, Peter Mandl², María Isabel Miguel³, Joan Blasi⁴, Maria Lopez-Lasanta¹, Sara Marsal¹, Maria-Antonietta D'Agostino⁵ and Ingrid Moller⁶, ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Universitat de Barcelona - Campus Bellvitge, Unitat d’anatomía i embriología humana, L'Hospitalet de Llobregat, Barcelona, Spain, ⁴Universitat de Barcelona - Campus Bellvitge, Histologia, L'Hospitalet de Llobregat, Barcelona, Spain, ⁵Universita Cattolica del Sacro Cuore Rome, Courbevoie, France, ⁶Instituto Poal de Reumatología, Barcelona, Spain
Background/Purpose: The digital annular pulleys (DAP) are anatomical structures of soft connective tissue organized as transverse fibers of variable width, thickness, and configuration that overlay…
Abstract Number: 1427 • ACR Convergence 2023
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
Kristi Mizelle¹, William R Tillett², Mira Ali³, Thomas Iyile³, Tianming Gao³, Arathi Setty³, Jessica A Walsh⁴ and Laura Coates⁵, ¹Tidewater Physicians Multispecialty Group, Newport News, VA, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³AbbVie, Inc., North Chicago, IL, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Involvement of weight-bearing joints in patients with PsA can be associated with reduced activities of daily living and quality of life. Upadacitinib (UPA) is…
Abstract Number: 1641 • ACR Convergence 2023
The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?
Selinde Snoeck Henkemans¹, Pascal de Jong¹, Jolanda J. Luime¹, Marc r. Kok², ilja Tchetverikov³, Annette van der Helm-van Mil⁴ and marijn vis¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In rheumatoid arthritis (RA), initiation of treatment within the window of opportunity, i.e. 12 weeks after symptom onset, results in higher remission rates, and…
Abstract Number: 1791 • ACR Convergence 2023
Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622
James Sullivan¹, Vandana Rai², Jennifer Harvey², Vincent Del Signore², Unnikrishnan Chandrasekharan² and M. Elaine Husni³, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Despite the widespread use of anti-TNFα therapy in psoriatic arthritis (PsA), a significant proportion of patients fail to achieve a complete treatment response. There…
Abstract Number: 2233 • ACR Convergence 2023
Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
Thomas Macleod¹, Xenofon Baraliakos², Emmanouil Rampakakis³, Warner Chen⁴, Antonius Pieter J Van Den Heuvel⁴, Loqmane Seridi⁴, May Shawi⁵, Frederic Lavie⁶, Joseph F. Merola⁷, Proton Rahman⁸ and Dennis McGonagle⁹, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Translational Sciences, Janssen Research & Development, LLC, Spring House, PA, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁹Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Neutrophils have potential pathogenic roles in chronic inflammatory diseases (e.g., neutrophilic cutaneous microabscesses in psoriasis, and neutrophils in the synovial fluid/tissue in PsA and…
Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Dafna Gladman¹, Laura Coates², Maarten de Wit³, Alexis R Ogdie⁴, Ana-Maria Orbai⁵, Barbara Ink⁶, Vanessa Taieb⁷, Jérémy Lambert⁸ and Laure Gossec⁹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Oxford, Oxford, United Kingdom, ³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Colombes, France, ⁸UCB Pharma, Irigny, France, ⁹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…
Abstract Number: 0168 • ACR Convergence 2023
What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
Nick Bansback¹, Alex Tam², Dafna Gladman³, Vathany Kulasingam⁴, Eldon Spackman⁵ and Vinod Chandran⁶, ¹University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Initiating treatment in patients with psoriasis (PsO) who have unrecognized Psoriatic arthritis (PsA) may slow disease progression and improve long-term outcomes. Several candidate biomarkers…
Abstract Number: 0489 • ACR Convergence 2023
Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
Asmir Vodencarevic¹, Jan Brandt-Juergens², Daniel Peterlik¹, Benjamin Gmeiner¹ and Uta Kiltz³, ¹Novartis Pharma GmbH, Nürnberg, Germany, ²rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Secukinumab (SEC) proved to be an effective treatment for patients with psoriatic arthritis (PsA) in previous randomized clinical trials [1]. There is only limited…
Abstract Number: 0505 • ACR Convergence 2023
Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study
Shashank Cheemalavagu¹, Yuxuan Jin² and M. Elaine Husni³, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH
Background/Purpose: Achieving minimal disease activity (MDA) is an important treatment goal in psoriatic arthritis (PsA), as it leads to improved clinical outcomes and quality of…
Abstract Number: 0780 • ACR Convergence 2023
Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with active psoriatic arthritis (PsA), a heterogeneous immune-mediated disease. IL-17 inhibition has…
Abstract Number: 1401 • ACR Convergence 2023
The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA
Gonul Hazal Koc¹, Marc r. Kok², Jolanda J. Luime¹, ilja Tchetverikov³, William R Tillett⁴, Fazira R. Kasiem¹, Lindy A. Korswagen⁵, J. Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Maikel van oosterhout⁸, P. Baudoin⁹, Petra Kok¹⁰, radboud J.e.m. Dolhain¹¹ and marijn vis¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Albert Sweitzer Hospital, Dordrecht, Netherlands, ⁴Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, Rotterdam, Netherlands, ⁷Haga Ziekenhuis, The Hague, Netherlands, ⁸Groene Hart Ziekenhuis, Gouda, Netherlands, ⁹Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ¹⁰Reinier de Graaf Gasthuis, Delft, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: A feasible, widely accepted, comprehensive disease activity measure is needed for daily use in psoriatic arthritis (PsA). Current measures are either complex (Psoriatic Arthritis…
Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 1642 • ACR Convergence 2023
Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort
Paras Karmacharya¹, Daniel W. Byrne², Alisa Stephens-Shields³, Leslie Crofford⁴, M. Elaine Husni⁵, Jose Scher⁶, Ethan Craig³, Robert Fitzsimmons³, Soumya Reddy⁷, Marina Nighat Magrey⁸, Jessica A Walsh⁹ and Alexis R Ogdie³, ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, PA, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁶New York University School of Medicine, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸Case Western Reserve University, University Hospitals, Cleveland, OH, ⁹Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Despite an increasing number of therapeutic options, less than one-third of patients with PsA achieve remission. A major cause of non-response is that PsA…
Abstract Number: 1792 • ACR Convergence 2023
Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis
Darshini Ganatra¹, Anas Samman¹, David Nasri¹, Sara Rahmati¹, Omar Cruz Correa¹, Rohan Machhar¹, Rajiv Gandhi², Mohit Kapoor³ and Vinod Chandran⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis and shares several clinical features with Osteoarthritis (OA), the most common form of arthritis. This often leads…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.